Cargando…

A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer

Medullary thyroid cancer (MTC) accounts for ~4% of all thyroid malignancies. MTC derives from the neural crest and secretes calcitonin (CTN) and carcinoembryonic antigen (CEA). Unlike differentiated thyroid cancer, MTC does not uptake iodine and I-131 RAI (radioactive iodine) treatment is ineffectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Rivero, Jaydira, Donahue, Renee N., Marté, Jennifer L., Gramza, Ann W., Bilusic, Marijo, Rauckhorst, Myrna, Cordes, Lisa, Merino, Maria J., Dahut, William L., Schlom, Jeffrey, Gulley, James L., Madan, Ravi A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427000/ https://www.ncbi.nlm.nih.gov/pubmed/32849281 http://dx.doi.org/10.3389/fendo.2020.00490

Ejemplares similares

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
por: Gatti‐Mays, Margaret E., et al.
Publicado: (2019)

Samarium-153-EDTMP (Quadramet(®)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
por: Heery, Christopher R., et al.
Publicado: (2016)

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
por: Abdul Sater, Houssein, et al.
Publicado: (2020)

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
por: Bilusic, Marijo, et al.
Publicado: (2022)

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
por: Madan, Ravi A, et al.
Publicado: (2021)

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer
por: Del Rivero, Jaydira, et al.
Publicado: (2018)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management
por: Marté, Jennifer L, et al.
Publicado: (2020)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
por: Karzai, Fatima, et al.
Publicado: (2018)

Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine
por: Madan, Ravi A., et al.
Publicado: (2023)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma
por: DeMaria, Peter Joseph, et al.
Publicado: (2021)

Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic
por: Donahue, Renee N, et al.
Publicado: (2021)

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
por: DeMaria, Peter J, et al.
Publicado: (2021)

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival
por: Grenga, Italia, et al.
Publicado: (2013)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
por: Strauss, Julius, et al.
Publicado: (2020)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response
por: Kim, Joseph W., et al.
Publicado: (2012)

Update on Targeted Therapy in Medullary Thyroid Cancer
por: Okafor, Christian, et al.
Publicado: (2021)

Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
por: Farsaci, Benedetto, et al.
Publicado: (2013)

Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
por: Peinetti, Nahuel, et al.
Publicado: (2022)

Anti-angiogenesis in prostate cancer: knocked down but not out
por: Bilusic, Marijo, et al.
Publicado: (2014)

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
por: Lepone, Lauren M., et al.
Publicado: (2016)

Perspectives on the clinical development of immunotherapy in prostate cancer
por: Cordes, Lisa M, et al.
Publicado: (2018)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer
por: Chen, Shih-Wei, et al.
Publicado: (2017)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
por: Chau, Vincent, et al.
Publicado: (2020)

Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report
por: Monge, Cecilia, et al.
Publicado: (2018)

Role of vaccine therapy in cancer: biology and practice
por: Schlom, J., et al.
Publicado: (2007)

Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report
por: Pastor, Danielle M., et al.
Publicado: (2020)

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer
por: Gatti-Mays, Margaret E., et al.
Publicado: (2021)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

Nivolumab-associated acute glomerulonephritis: a case report and literature review
por: Jung, Kyungsuk, et al.
Publicado: (2016)

Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM
por: Singh, Harpreet, et al.
Publicado: (2014)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Assessment of Aortoiliac Atherosclerotic Plaque on CT in Prostate Cancer Patients Undergoing Treatment
por: Lee, Sungwon, et al.
Publicado: (2022)

Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises
por: Aragon-Ching, Jeanny B., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_u6j04b5rk25la59ge6tb82bpc7